AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015






<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://photos.prnewswire.com/prnvar/20150727/245825LOGO?max=400 –>















LAS VEGAS, July 31, 2015 /PRNewswire/ — In today’s fast changing healthcare environment, independent pharmacists seek resources that insight them drive positive healthiness outcomes, improve profitability and improve their role as a necessary source of patient care in their communities. At ThoughtSpot 2015, Good Neighbor Pharmacy’s annual tradeshow and conference, AmerisourceBergen announced a brand-new set of innovative capabilities that will certainly strengthen its Pharmacy Services Administration Organization and insight independent pharmacies endure the industry’s most pressing challenges, including stress on profit margins, narrowing networks and reimbursement challenges. 

“AmerisourceBergen and Good Neighbor Pharmacy are committed to providing community pharmacists along with the resources they have to transform their businesses, adapt to industry adjustments and to leverage their collective voice to shape the delivery of pharmacy services,” said David Neu, executive vice president of retail strategy at AmerisourceBergen and president of Good Neighbor Pharmacy. “Over the past year we’ve gained a collection of targeted investments that will certainly support independent pharmacies in their efforts to improve patient care and receive reasonable and accurate reimbursement for their services.”

During today’s general session, AmerisourceBergen leaders unveiled the organization’s revamped Pharmacy Services Administration Organization. Bolstered by a core of enhanced capabilities, the newly-named Elevate Provider Network will certainly support independent pharmacies in their efforts to improve profitability through enhanced patient care, much better business practices and by leveraging centralized data to support reimbursement discussions along with payers. Highlights of the brand-new service, which will certainly allow Good Neighbor Pharmacy to Give its network members access to its Premier-level services, include:  

  • A brand-new patient engagement focus and capability set, powered by PrescribeWellness, that independent pharmacies can easily leverage to drive adherence and improve patient care, ultimately developing the potential to improve CMS Star ratings and enhance reimbursements  
  • Access to pre- and post-claims editing services through Emdeon, a leading provider of revenue and payment cycle management, which will certainly insight reduce claim errors, improve pharmacy profits and Give better transparency in to payer reimbursement
  • An expansion of its central pay capabilities along with the addition of claim reconciliation services powered by FDS, Inc., which enables pharmacists to monitor their receivables balance
  • A revamped InSite pharmacy performance tool that will certainly now include front-of-store sales data displayed in its popular peer benchmarking view, allowing pharmacies to measure performance versus similar stores 
  • A brand-new mobile application that will certainly notify pharmacists of crucial post they have to control their business at the touch of a finger, such as the next day’s bank deposits and a six-month trending view of their performance in the four highly-rated CMS Star clinical measures

“AmerisourceBergen believes that community pharmacy is a crucial delivery point for high-quality and accessible healthiness care. It’s a terrific and humbling responsibility to Give pharmacists along with the resources they have to optimize and grow their businesses,” Mr. Neu said. “The enhancements announced today will certainly support the delivery of true community healthcare by enabling independent pharmacists to further support patients, operate their pharmacies effectively and combat growing industry challenges surrounding reimbursement.”

Good Neighbor Pharmacy’s 2015 Pharmacy of the Year Award was announced Throughout general session. Topeka Pharmacy received the esteemed award for exemplifying exactly what it means to be a Good Neighbor Pharmacy in their commitment to boosting patient care and lives in local communities.

During the general session, AmerisourceBergen leaders announced that the company pledged to suit up to $50,000 for any type of contributions gained to the National Community Pharmacists Association Foundation (NCPAF) between July 30 and August 31. The donation will certainly benefit the Foundation’s disaster relief and pharmacy advice fund and support independent community pharmacies that are affected by natural disaster or others edge circumstances.

For a lot more post on the ThoughtSpot conference, please visit: http://www.thoughtspot2015.com/.

About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, aiding both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and improve patient care. along with services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human medicine and animal health. along with over $120 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 16,000 people. AmerisourceBergen is ranked #16 on the Fortune 500 list. For a lot more information, go to www.amerisourcebergen.com.

Logo – http://photos.prnewswire.com/prnh/20150727/245825LOGO

SOURCE AmerisourceBergen

RELATED LINKS
http://www.amerisourcebergen.com

New computer-based technology may lead to improvements in facial transplantation

ollowing several years of research and collaboration, physicians and engineers at Johns Hopkins and Walter Reed National Military Medical Focus say they have actually created a computer platform that provides rapid, real-time feedback prior to and throughout facial transplant surgery, which might someday boost face-jaw-teeth alignment between donor and recipient.

Surgeons performed the very first successful transplant of facial features, including the jaw and teeth, in 2008, mainly relying on visual judgment. Due to the fact that then, about 30 facial transplants have actually been done worldwide, costing an estimated $250,000 to $500,000. These transplants have actually led to the improvement of patient survival and enhancement of bodily appearances. However, current surgical ways frequently leave patients along with some undesired residual deformities and abnormalities in function.

The brand-new computer-assisted development ought to make it much less most likely to misalign the brand-new set of bones, jaw and teeth, and stay clear of various other reconstructive abnormalities for patients along with significant craniofacial trauma, the researchers report.

Use of the brand-new platform in mock surgeries performed on plastic and cadaveric human donor/recipient pairs is described in the diary Plastic and Reconstructive Surgery, published in August.

Called the computer-assisted preparing and execution (CAPE) system, the platform is very first used to recommendations strategy surgery once a donor has actually been identified for transplantation. Using write-up from CT scans, the donor’s anatomy is matched to the recipient’s anatomy in an effort to optimize form, or appearance, and function, such as chewing and breathing, according senior author Chad Gordon, D.O., an assistant professor of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine and co-director of the Multidisciplinary Adult Cranioplasty Focus at Johns Hopkins.

The execution part of the system’s name refers to the technology used throughout surgery, which involves a novel feature known as real-time cephalometry (RTC), says Gordon. RTC provides the surgeon along with target measurements and angles related to ideal jaw-teeth positions, along with instantaneous visual feedback in the operating room unlike ever before.

“Every time the donor’s jaw-teeth segment moves throughout facial transplant inset, the computer recalculates its movements in comparison to the face transplant recipient, meaning the surgical group can easily have actually unprecedented visual data in achieving ideal alignment of the face, jaw and teeth,” explains Gordon. His collaborators included faculty members and scientists at the Johns Hopkins University Whiting School of Engineering and Applied Physics Laboratory.

The preciseness of the technology will certainly most likely reduce the demand for patients to undergo revision surgery and will certainly recommendations to boost outcomes in various areas, says Gordon.

Gordon and his colleagues have actually jointly filed for eight patents related to the system, which has actually various applications within the field of craniomaxillofacial surgery.

For the study, the group performed donor-to-recipient, Le Fort-based face-jaw-teeth transplantation on two plastic models and two human cadavers using the CAPE system.

Gordon says the latest prototype system can easily help face-jaw-teeth transplantation, known as Le Fort-based jaw surgery, and can easily recommendations surgeons in all of forms and types of craniofacial surgery, in the 2 adults and children.

“CAPE and RTC can easily be adapted for use in various other surgical disciplines, such as oral-maxillofacial surgery, head and neck surgery, and neurosurgery,” adds co-author Mehran Armand, Ph.D., director of Biomechanical- and Image-Guided Surgical Systems, a collaborative laboratory between the Applied Physics Laboratory and Whiting School of Engineering. “In fact, they share principles along with our biomechanical advice system, which was previously created for orthopaedic surgery through a grant funded by the National Institute of Biomedical Imaging and Bioengineering.”

The group members at Walter Reed National Military Medical Focus might locate the system especially valuable for treating victims of improvised explosive device blasts that have actually survived however are severely deformed and demand reconstruction, according to Gerald Grant, service chief of the 3D Medical Applications Focus at Walter Reed. “RTC will certainly offer our group along with a much-called for advantage once it involves reconstructing wounded warriors along with devastating maxillofacial or mandibular injuries, the 2 for transplant surgery and for book reconstruction,” he says.

Looking Good For Summer Fun In Orange County

Summer is officially here, and there’s no much better means to take pleasure in the season compared to obtaining outside and soaking up some sun and neighborhood flavor. Orange County, California is the place to be for countless outdoor festivals, markets and neighborhood events taking put all of summer long.

Once the weather gets nice, there’s no demand to leave to see anywhere else and miss the fun. Lots of of Orange County’s summer festivals are so dog centralized, it would certainly be a lot more fitting to classify them as person-friendly fairly compared to pet-friendly. The annual Pet Festival in Westminster, draws wide crowds. The day will certainly include demonstrations including agility, flyball, Frisbee, nosework, search and rescue; a Ideal trick contest; a silent auction; and an AKC Dog Great Citizen clinic and certification. A fashion reveal will certainly showcase the most recent in Dog couture. It’s sure to be an exciting day for human and hound alike.

Summer is the ideal season to discover fresh produce. Support neighborhood farmers and vendors at the Farmers Market at UCI on weekends. Neighborhood and local give an ambiance ideal for perusing artisanal honeys and breads, impeccably fresh and neighborhood produce, meat, fish and wine. While each market’s offerings vary, the “Harvest Calendar” forecasts just what is most likely to be available. The market sellers are out in force come rain or shine.

Halaven® (éribuline) : Eisai dépose des demandes d’enregistrement simultanément aux Etats Unis, au Japon et UE pour le traitement du sarcome des tissus mous






HATFIELD, Angleterre, July 31, 2015 /PRNewswire/ —

Une demande de variation de type II a ete soumise  en union europeenne, pour l’expansion d’indication d’ Halaven® (eribulin) dans le traitement des patients atteints de sarcome des tissus mous, non resecable ayant recu au préalable une chimiothérapie pour maladie localement avancée ou metastatique. L’efficacité et la sécurité ont été établies principalement chez des patients atteints de léiomyosarcomes et de liposarcomes (sarcomes adipocytaires), qui représentent environ 30 % des sarcomes des tissus mous. Des demandes semblables ont également été déposées aux États-Unis et au Japon.

L’essai clinique pivot de la demande d’AMM, est un essai de phase III, comparatif versus dacarbazine, traitement standard actuel.[1] Dans cette étude 309, l’éribuline a amélioré la Survie Globale (SG) médiane des patients de 13,5 mois contre 11,5 mois sous dacarbazine, soit une amélioration significative (HR : 0,768; IC à 95 %: 0,618-0,954; p = 0,017) et a donc répondu à son objectif principal. Cette étude constitue le premier et le seul essai clinique contrôlé et randomisé portant sur une monothérapie systémique qui mette en évidence une amélioration de la SG de personnes précédemment traitées pour un sarcome des tissus mous à ce stade de la maladie. Ces données ont été présentées dans le cadre d’une communication orale lors du congrès de juin 201five de l’American Society of Clinical Oncology (ASCO).

« En tant que médecins traitant des sarcomes des tissus mous, nous sommes en demande de nouvelles selections thérapeutiques pouvant prolonger la survie des patients souffrant de ces cancers agressifs et difficiles à traiter. Il est prouvé que léribuline permet une amélioration de la survie globale par rapport à la dacarbazine et jespère que les médecins et leurs patients auront rapidement accès à ce nouveau traitement, tellement important », a commenté le Professeur Patrick Schöffski, chef du service d’oncologie médicale générale à l’Hôpital universitaire de Louvain, en Belgique.

« Confirmant lengagement dEisai à venir en aide aux personnes souffrant de cancers rares, ces demandes représentent une avancée très importante pour les patients atteints dun sarcome des tissus mous, et leurs familles. Nous savons que léribuline a un mode daction différent et puissant et létude 309 a confirmé quelle permet daméliorer la survie globale dans le traitement de cancers complexes et agressifs » a expliqué Gary Hendler, PDG d’Eisai EMEA et Président d’Eisai Oncology Global Company Unit.

Les sarcomes des tissus mous sont des cancers qui se développent à partir des cellules des tissus mous de soutien du corps, tels que les tissus adipeux, musculaires, nerveux, fibreux et vasculaires.[2] Les léiomyosarcomes sont l’un des types de sarcomes les plus fréquents chez l’adulte. Ils se développent à partir des cellules des muscles lisses et peuvent apparaître en tout point du corps.[2] Les liposarcomes (sarcomes adipocytaires) prolifèrent à partir des adipocytes et peuvent également apparaître en tout point du corps. Les léiomyosarcomes et les liposarcomes représentent environ 30 % des sarcomes des tissus mous.[3]

Bien que les sarcomes des tissus mous soient relativement rares, il reste un besoin médical à satisfaire pour les patients qui, bien souvent, ne répondent pas au traitement et dont le pronostic est mauvais.[8]

L’essai 309 était une étude clinique de phase III randomisée, multicentrique et menée en ouvert, visant à comparer l’efficacité et la sécurité de l’éribuline à celles de la dacarbazine chez 452 patients (d’au moins 18 ans). Les patients recrutés dans l’étude présentaient un léiomyosarcome ou un liposarcome. Ceux qui souffraient d’un sarcome des tissus mous localement avancé ou en rechute et métastatique, ayant continué à progresser après des traitements standard, devaient avoir été traités par une anthracycline et avoir reçu au moins un autre traitement antérieur.[4]

En Europe, environ 29 000 diagnostics de sarcomes des tissus mous sont portés chaque année.[5] L’incidence annuelle des sarcomes des tissus mous est d’environ 350 000 cas dans le monde.[7]

Les événements indésirables les plus souvent observés dans le bras éribuline étaient la neutropénie, la fatigue, les nausées, l’alopécie et la constipation.[4]

L’éribuline est le premier médicament inhibiteur de la dynamique des microtubules appartenant à la classe des halichondrines et ayant un mécanisme d’action innovant. D’un point de vue structurel, l’éribuline est un analogue de synthèse simplifié de l’halichondrine B, molécule isolée d’Halichondria okadaï, une éponge marine. L’éribuline agirait en inhibant la phase de croissance de la dynamique des microtubules, empêchant la division cellulaire.

L’éribuline est actuellement indiquée pour le traitement des patientes atteintes d’un cancer du sein localement avancé ou métastatique, dont la maladie a progressé après au moins un protocole de chimiothérapie pour le traitement du stade avancé. Le traitement antérieur adjuvant ou du cancer métastatique doit avoir comporté une anthracycline et un taxane, sauf chez les patients ne pouvant pas recevoir ces traitements. [6]

Eisai travaille à la découverte, au développement et à la production de traitements anticancéreux innovants pouvant faire la différence et changer la vie des patients et de leurs familles. Cette passion pour l’être humain fait partie intégrante de la mission human good health care (hhc) d’Eisai, qui s’efforce de permettre une meilleure compréhension des besoins des patients et de leurs familles afin d’accroître les bienfaits des soins de santé.

Notes à lattention des rédacteurs  

À propos des sarcomes des tissus mous 

Le terme « sarcome des tissus mous » est utilisé pour désigner collectivement un groupe varié de tumeurs malignes.

Les léiomyosarcomes sont l’un des types de sarcomes les plus fréquents chez l’adulte. Ils se développent à partir des cellules des muscles lisses. Les muscles lisses sont constitués de fibres musculaires qui se contractent lentement de façon indépendante de la volonté. Ils sont présents dans la paroi des organes musculaires, tels que le cœur et l’estomac, ainsi que dans les parois des vaisseaux sanguins du corps entier. Ainsi, les léiomyosarcomes peuvent apparaître en tout point du corps. On les retrouve fréquemment dans la paroi utérine, le tronc, les bras et les jambes.[2]

Les liposarcomes (sarcomes adipocytaires) prolifèrent à partir des adipocytes et peuvent également apparaître en tout point du corps. Ils touchent deux fois plus l’homme que la femme.[7] Les léiomyosarcomes et les liposarcomes représentent environ 30 % des sarcomes des tissus mous.[3]

Contrairement à d’autres cancers, tels que le cancer du poumon non à petites cellules (CPNPC), les sarcomes des tissus mous diagnostiqués touchent principalement une zone localisée, et nombreux sont ceux qui relèvent d’une ablation chirurgicale complète. Le taux de rechute peut néanmoins atteindre 50%.[8]

Le pronostic de survie des patients à un stade avancé de la maladie est péjoratif, avec une survie médiane avoisinant un an, voire moins. En raison de la rareté de ces tumeurs, les éléments de preuve des facteurs pronostics sont faibles et mal compris.[9]

Étude clinique de phase III mondiale 309[4]

Le critère d’évaluation principal de l’étude portait sur la comparaison de la survie globale entre les deux bras de traitement et les critères d’évaluation secondaires comprenaient la survie sans progress et la qualité de vie.

Des patients âgés d’au moins 18 ans, souffrant d’un léiomyosarcome de stade avancé de grade élevé ou intermédiaire ou de formes dédifférenciées, myxoïdes, à cellules rondes ou pléomorphes de sarcome adipocytaire (ADI) incurable par chirurgie et/ou radiothérapie, ont été recrutés dans l’étude. Ils avaient un indice de performance ECOG ≤ 2 et avaient reçu ≥ 2 traitements systémiques standard, dont une anthracycline. Ils ont été randomisés selon un rapport 1:1 pour recevoir de l’éribuline (1,4 mg/m[2], par voie IV à J1 et J8) ou de la dacarbazine (850-1 200 mg/m[2], par voie IV à J1) tous les 21 jours jusqu’à progress de la maladie.

Au total, 452 patients (67 % de femmes ; 79 % < 65 ans) ont été randomisés (228 dans le bras sous éribuline ; 224 dans le bras sous dacarbazine). La SG médiane pour l’éribuline et la dacarbazine était respectivement de 13,five et 11,5 mois (HR = 0,768, IC à 95 % 0,618-0,954 ; p = 0,017). La SSP était respectivement de 2,6 mois dans les deux bras (HR = 0,877, IC à 95 % 0,710-1,085 ; p = 0,229). Le taux de SSP en semaine 12 était de 33 % et 29 % pour l’éribuline et la dacarbazine. Le profil de toxicité de l’éribuline concordait avec l’expérience antérieure, sans résultat inattendu ni inédit en matière de sécurité d’emploi. Dans cette étude, les événements indésirables les plus souvent observés dans le bras sous éribuline étaient la neutropénie, la fatigue, les nausées, l’alopécie et la constipation, ce qui concorde avec le profil connu de l’éribuline

Eisai en oncologie  

L’engagement d’Eisai à faire progresser significativement la recherche en oncologie est fondé sur l’knowledge scientifique, et repose sur la capacité du laboratoire à réaliser des recherches et des découvertes précliniques sur un strategy international, à développer des molécules, des vaccins thérapeutiques, des thérapies biologiques et des soins de assist en cancérologie dans de multiples indications.

À propos dEisai EMEA en oncologie 

Eisai se consacre au développement et à la mise à disposition de nouveaux traitements à haute valeur ajoutée pour améliorer la qualité de vie des patients souffrant d’un cancer. C’est pourquoi le développement de traitements anticancéreux représente un défi de première importance pour Eisai en Europe, au Moyen-Orient, en Afrique, en Russie et dans l’Océanie (EMEA).

À propos dEISAI Co. Ltd. 

Eisai Co. Ltd. est l’un des plus grands groupes pharmaceutiques mondiaux se consacrant à la recherche et au développement de nouveaux médicaments. Son siège social est au Japon. La mission de l’entreprise est de « penser d’abord aux patients et à leurs familles et augmenter les bénéfices des soins de santé », ce qu’EISAI appelle la philosophie du human good health care (hhc). Avec plus de 10 000 collaborateurs travaillant au sein de son réseau global de centres de R&D, de sites de production et des filiales commerciales, le groupe s’efforce de mettre sa philosophie hhc en œuvre en développant des produits innovants dans différents domaines thérapeutiques dans lesquels de nombreux besoins médicaux restent insatisfaits, notamment l’oncologie et la neurologie.

En tant que groupe pharmaceutique mondial, la mission d’Eisai concerne les patients du monde entier, grâce à ses investissements et à sa participation à des initiatives basées sur des partenariats, visant à améliorer l’accès aux médicaments dans les pays en développement et émergents.

Pour plus d’informations à propos d’Eisai Co. Ltd., veuillez consulter le site http://www.eisai.com

Bibliographie 

  1. Schöffski P et al. Randomized, open-label, multicenter, phase three study of eribulin versus dacarbazine in patients (pts) along with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).  American Society of Clinical Oncology annual meeting 2015; Abstract #LBA10502
  2. Macmillan. Exactly what are soft tissue sarcomas? http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/Aboutsofttissuesarcomas/Softtissuesarcomas.aspx . Accessed: July 2015
  3. Cancer Research UK, Soft Tissue Sarcoma Incidence Statistics: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/soft-tissue-sarcoma/incidence/ Accessed: July 2015
  4. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01327885?term=halaven+soft+tissue+sarcoma&rank=2 Accessed: July 2015
  5. ESMO Guidance: http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Accessed: July 2015
  6. SPC Halaven (updated June 2014). Readily available at:http://www.medicines.org.uk/emc/medicine/24382/SPC/Halaven+0.44+mg+ml+solution+for+injection/ Accessed: July 2015
  7. National Cancer Institute.http://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page1. Accessed: July 2015
  8. R. Pollock. Soft Tissue Sarcomas: A Volume in the American Cancer Society Atlas of Clinical Oncology Series. 2012
  9. Fletcher et al. Globe good health Organization Classification of Tumours of Soft Tissue and Bone (4th Edition). Lyon: IARC Press, 2013.

Date de préparation : Julliet 2015

Code du projet : Halaven-UK0437a

 

SOURCE Eisai

When surgeons listen to their preferred music, their stitches are better and faster

A brand-new study from The University of Texas Medical Branch at Galveston shows that as soon as plastic surgeons listen to music they prefer, their surgical technique and efficiency as soon as closing incisions is improved. The study is currently available in the Aesthetic Surgery Journal.

From classical to rock, music can easily be heard in operating rooms across the world. Even though previous studies have actually revealed that listening to music throughout operations can easily reduced the pressure levels of surgeons, there is limited short article on the effects of music on technical performance while completing a surgical task, such as closing incisions. Stitching prowess and rate is especially necessary for plastic surgeons.

Fifteen plastic surgery residents were asked to close incisions along with layered stitches on pigs’ feet obtained at a neighborhood meals market — pigs’ feet are widely accepted as just like human skin.

The residents were not informed of the purpose of the study. They were asked to do their finest and to notify the researchers as soon as they completed a closure. The day after the initial incision closing exercise, the residents were asked to do one more repair using identical technique along with the music either being turned on or off, in opposition to the initial closure. They were not told that the researchers were comparing times or that the outcomes would certainly be graded until the study was completed.

“We recognized that our subjects could potentially enhance on the second repair just as the result of repetition,” said author Dr. Shelby Lies, the UTMB chief plastic surgery resident. “This effect was low by randomly assigning the residents to music initial or no music initial groups.”

The standard repair completion time for every one of residents was 7 percent shorter as soon as their favorite music was playing. This effect was magnified as the experience of the surgeon grew. Playing their favorite music led to a 10 percent reduction of repair time for senior residents as compared to an 8 percent time reduction seen in the junior residents.

“Spending much less time in the operating room can easily translate in to considerable cost reductions, particularly as soon as incision closure is a large part of the procedure, such as in a tummy tuck,” said Lies. “Longer duration under general anesthesia is additionally linked along with increased risk of side events for the patient.”

The quality of the job was judged by plastic surgeons that did not already know whose job they were analyzing or others conditions of the study. The judges’ ratings confirmed an overall improvement in repair quality while music was played, regardless of whether the resident did the repair along with their music initial or second.

“Our study confirmed that listening to the surgeon’s favorite music boosts efficiency and quality of wound closure, which might translate to healthiness care cost savings and much better patient outcomes,” said author Dr. Andrew Zhang, UTMB assistant professor of surgery in the division of plastic and reconstructive surgery.

Story Source:

The above write-up is reprinted from materials given by University of Texas Medical Branch at Galveston. Note: components could be edited for content and length.